Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Diagnocure Gains Rights to New Prostate Cancer Genes

  • DiagnoCure acquired specific rights and commissioned further research on new genes that show promise as prostate cancer markers. The agreement, signed with Radboud University Medical Center, Nijmegen, the Netherlands, covers technology rights related to Dr. Jack Schalken’s discoveries of the role of FOX gene expression in prostate cancer and commissions further research into the diagnostic, prognostic, and therapeutic potential of those genes.

    “We have sufficient evidence to indicate that specific FOX genes may further enhance the diagnostic efficacy of the PCA3 gene, which in itself reflects a dramatic improvement over PSA testing,” asserts Dr. Schalken.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »